Navigation Links
Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent
Date:10/12/2008

e-matched TAXUS Express(TM) Stent control group.

In spite of more complex patients treated with the TAXUS Liberte Stent, the adjusted data demonstrated that the safety and efficacy benefits of the TAXUS Liberte Stent System were maintained at three years in workhorse lesions. The study reported similar rates of target lesion revascularization (TLR) of 9.3 percent for the TAXUS Liberte Stent vs. 9.6 percent for the TAXUS Express control stent (p=0.81). Three-year data also showed comparable rates of cardiac death (3.4 percent for the TAXUS Liberte Stent vs. 2.3 percent for the TAXUS Express Stent, p=0.20) and overall myocardial infarction (MI) (5.2 percent for the TAXUS Liberte Stent vs. 6.3 percent for the TAXUS Express Stent, p=0.36). The adjusted rate of ARC definite/probable stent thrombosis at three years for the TAXUS Liberte Stent group was 2.0 percent, as compared to 2.2 percent for the control group (p=0.76). Since the trial's primary end point was reported at nine months, the overall target vessel revascularization (TVR) rate through three years was significantly lower for the TAXUS Liberte Stent group (6.1 percent versus 9.1 percent for control, p=0.0178), suggesting a late benefit of the thin-strut TAXUS Liberte Stent.

TAXUS ATLAS Direct Stent

Dr. Turco also presented two-year data from the TAXUS ATLAS Direct Stent clinical trial, a 247-patient study assessing the safety of direct stenting with the TAXUS Liberte Stent compared to placement of a TAXUS Liberte Stent using balloon pre-dilatation. The control arm for the trial is the angiographic cohort of the TAXUS ATLAS Workhorse clinical trial, which mandated pre-dilatation. Although the ATLAS Workhorse and ATLAS Direct Stent trials had the same inclusion and exclusion criteria, simpler lesions were selected for the direct stent group.

The study reported a low two-year adjusted overall MACE (major adverse cardiac events) rate of 11.2 percent for the direct stent group, as compar
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program
2. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
3. TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
4. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
5. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
6. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
7. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
8. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
9. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
10. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
11. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)... Successful Results from prior U.S., U.K. and Chin...Vital Therapies, Inc. (VTI), a development stage c...tient enrollment has begun for a randomized, contr...ill study the Extracorporeal Liver Assist Device (... Failure (ALF) under three protocols. The study is...
(Date:1/6/2009).... 6 In recent controlled studies c...mphis , scientists found that the patented ingredi...nd only proven ingredient to increase levels of ni...ood nitrate/nitrate (NOx) in human subjects. , ,...n increase in blood flow to the skeletal muscles. ...
(Date:1/6/2009)...n. 6 Sequella, Inc., a ...n diseases of epidemic potential, announced today ...ent of tuberculosis (TB), was the first drug appro...gram contract to Dynport Vaccine Company LLC and Q...he National Institute of Allergy and Infectious Di...
(Date:1/6/2009)...J., Jan. 6 Pacira Pharmaceuticals,...pany, announced today that enrollment,has been co...evaluate the,safety and efficacy of a single intr...ivacaine) for prolonged postoperative analgesia. ,...my and in total knee,arthroplasty (TKA) are expec...
Breaking Medicine Technology:ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3 C O R R E C T I O N from Source Resverlogix Corp 5055 1 C O R R E C T I O N from Source Resverlogix Corp 5055 2Cold Spring Harbor Protocols features classic approaches for analyzing chromosomes 3151 1ACC Observes National Drinking Water Week 18231 1ACC Observes National Drinking Water Week 18231 2Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast 5052 1Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast 5052 2Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast 5052 3
(Date:1/8/2009)...sessment for heart risk may not be accurate in som...News) -- Two studies, from the United States and t... the long-established Framingham Risk Score in pre..., The Framingham score, based on findings of a de...allows doctors to assess risk on the basis of seve...
(Date:1/8/2009)...PRNewswire/ -- A study released this week showing ...rom multiple chronic diseases shines a much-needed...re system to one that focuses on primary and secon...cine, the leader in disease prevention. , , (...06/NETU129LOGO ) , , The study, conducted by ...
(Date:1/8/2009)... sitting on the surface of cancer cells are keys t...reating and stopping the spread of certain types o...e, breast, ovarian and lung, among others. Armed ...teway for Cancer Research, an Illinois-based phila...o, M.D., Ph.D., and her co-workers at the Moores C...
(Date:1/8/2009)...ude study could shape new treatments for secondary...re-USNewswire/ -- Scientists at St. Jude Children,...tive treatment for bacterial pneumonia following i...cin and azithromycin, which kill bacteria by inhib...than a standard first-line treatment with the "bet...
Breaking Medicine News(10 mins):Health News:Studies Challenge Framingham Risk Score 2Health News:Studies Challenge Framingham Risk Score 3Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot' 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3
...! New research released on Monday suggests that a ... healthy and prolongs life. These findings stem fr...e in nuns. "It's been known for years that patholo...ssion or hostility can lead to illness," said Davi...
... during clinical trials, may be the in thing in AI...e HIV from circulating blood, has been developed a... mark the beginning of the end of HIV’s vicious gr...rs at Aethlon Medical, a biotechnology firm in La ...
..., may opt for mastectomy over breast-conserving lu... gene mutation, researchers said California on Mon...sed by an inherited genetic susceptibility. The ma...utations or alterations in two genes, BRCA1 and BR...
... AIDS therapy, complimentary and alternative medic...e patients, according to a new study. Among 191 HI... complementary and alternative therapies, 67% said...t to control their HIV infection and 40% reported ...
Other Medicine News:
... modular external fixation system designed to acco...needs. Originally marketed in Europe under the Fix...y of clinical use in the global healthcare marketp...rov technique begun in Russia over 50 years ago, R...
...N AVIA tonometer is an easy-to-use, hand-held inst...trongly with Goldmann tonometry. TONO-PEN AVIA has...tronic measurement technology that enables operato... minimal training. TONO-PEN AVIA is powered by a l...
The QuickLink™ Delivery System is a cartridge based device designed to assemble brachytherapy seeds, spacers and SourceLink Connectors into seed trains of variable lengths and with variable seed
...ollection benefits from innovative research in mat...ectors such as the aerospace and automotive indust... and the footwear and textile industry. , ,This kn...Carrera sunglasses collection to create unique and...
Medicine Products: